Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure

Show full item record



Permalink

http://hdl.handle.net/10138/297934

Citation

Bonnet , D , Berger , F , Jokinen , E , Kantor , P F & Daubeney , P E F 2017 , ' Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure ' , Journal of the American College of Cardiology , vol. 70 , no. 10 , pp. 1262-1272 . https://doi.org/10.1016/j.jacc.2017.07.725

Title: Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure
Author: Bonnet, Damien; Berger, Felix; Jokinen, Eero; Kantor, Paul F.; Daubeney, Piers E. F.
Contributor: University of Helsinki, Children's Hospital
Date: 2017-09-05
Language: eng
Number of pages: 11
Belongs to series: Journal of the American College of Cardiology
ISSN: 0735-1097
URI: http://hdl.handle.net/10138/297934
Abstract: BACKGROUND Heart rate reduction as a therapeutic target has been investigated in adults with heart failure (HF). Ivabradine has shown promising efficacy, but has not been evaluated in children. Currently, treatment recommendations for chronic pediatric HF are based mainly on chronic HF guidelines for adults. OBJECTIVES The authors explored the dose-response relationship of ivabradine in children with dilated cardiomyopathy and symptomatic chronic HF. The primary endpoint was >= 20% reduction in heart rate from baseline without inducing bradycardia or symptoms. METHODS This was a randomized, double-blind, placebo-controlled, phase II/III study with 12 months of follow-up. Children (n = 116) receiving stable HF therapy were randomized to either ivabradine or placebo. After an initial titration period, the dose was adjusted to attain the primary endpoint. Left ventricular function (echocardiography), clinical status (New York Heart Association functional class or Ross class), N-terminal pro-B-type natriuretic peptide, and quality of life (QOL) were assessed. RESULTS The primary endpoint was reached by 51 of 73 children taking ivabradine (70%) versus 5 of 41 taking placebo (12%) at varying doses (odds ratio: 17.24; p <0.0001). Between baseline and 12 months, there was a greater increase in left ventricular ejection fraction in patients taking ivabradine than placebo (13.5% vs. 6.9%; p = 0.024). New York Heart Association functional class or Ross class improved more with ivabradine at 12 months than placebo (38% vs. 25%; p = 0.24). There was a trend toward improvement in QOL for ivabradine versus placebo (p = 0.053). N-terminal pro-B-type natriuretic peptide levels decreased similarly in both groups. Adverse events were reported at similar frequencies for ivabradine and placebo. CONCLUSIONS Ivabradine safely reduced the resting heart rate of children with chronic HF and dilated cardiomyopathy. Ivabradine's effect on heart rate was variable, highlighting the importance of dose titration. Ivabradine treatment improved left ventricular ejection fraction, and clinical status and QOL showed favorable trends. (Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure from ages 6 months to 18 years; ISRCTN60567801) (C) 2017 by the American College of Cardiology Foundation.
Subject: heart rate
left ventricular ejection fraction
N-terminal pro-B-type natriuretic peptide
pediatric
quality of life
PEDIATRIC POPULATION
CONTROLLED-TRIAL
OUTCOMES
GUIDELINES
SOCIETY
ASSOCIATION
ADOLESCENTS
CARVEDILOL
STRATEGIES
MANAGEMENT
3121 General medicine, internal medicine and other clinical medicine
3123 Gynaecology and paediatrics
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S0735109717388150_main.pdf 1.194Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record